Division for Paediatric Stem Cell Transplantation -
Prof. Dr. med. Peter Bader |
|
| |
| |
> |
Profile
ZAFES member Prof. Bader is Head of the Division for Paediatric Stem Cell Transplantation in the University Children’s Hospital Clinic III (Director: Prof. Dr. med. T. Klingebiel). In the Division for Stem Cell Transplantation all modern transplantation procedures are performed. Amongst high dose chemotherapy with retransfusion of autologous stem cells transplantation from HLA-identical and non-identical family and unrelated donors are performed. Special research programs are running in the field of haploidentical transplantation with purified peripheral blood stem cells. The Division for Stem Cell Transplantation as well as the
Clinic III for paediatric haematology are certified by the German Society for Blood and Marrow Transplantation.
Expertise and research programs of the Division for Stem Cell Transplantation:
- Further development of stem cell therapies in malignant and non-malignant diseases
- Mesenchymal stem cell characterization and therapeutic usage in the treatment of GvHD and induction of tolerance
- Detection of impending relapse after allogeneic stem cell transplantation by the use of molecular techniques
- Development of cellular immunotherapy especially from tumour- and leukaemia specific T-cells, NK-cells and cytokine induced killer cells.
- Different clinical therapy studies
- Development of clinical trials
|
|
> |
Methods
- Flow cytometry , MACS, Elispot, Europium cytotoxicity tests
- Real-Time-PCR, conventional PCR-systems, Reverse transcriptase-PCR, Sequencing
- Cell biology, culturing and expansion
- Different mouse models
|
> |
Publications
- P. Bader, H. Kreyenberg, J. Beck, J. Hancock, N. Goulden, T. Oakhill, C. Steward, R. Handgretinger, D. Niethammer, T. Klingebiel. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post transplant outcome in children with ALL. Leukemia 2002; 16: 1668-1672.
- P. Bader, H. Kreyenberg, W. Hoelle, G. Dueckers, R. Handgretinger, P. Lang, B. Kremens, D. Dilloo, KW. Sykora, M. Schrappe, C. Niemeyer, A. v. Stackelberg, B. Gruhn, G. Henze, J. Greil, D. Niethammer, K. Dietz, J. F. Beck, T. Klingebiel. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with ALL after allogeneic SCT – Possible role for preemptive immunotherapy? J Clin Oncol 2004: 22(9); 1696-1705.
- S. Kuci, J. Wessels, HJ. Bühring, K. Schilbach, M. Schumm, G. Seitz, J. Löffler, P. Bader, PG. Schlegel, D. Niethammer, R. Handgretinger. Identification of a novel class of human adherent CD 34 neg. stem cells that give rist to SCID-repopulating cells. Blood 2003; 1: 869-876.
- G. Kerst, H. Kreyenberg, C. Roth, C. Well, K. Dietz, E. Coustan-Smith, D. Campana, E. Koscielniak, C. Niemeyer, PG. Schlegel, I. Müller, D. Niethammer, P. Bader. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukemia by flow cytometry and real-time PCR. Br J Haematology 2005;128(6):774-82.
- A. Willasch, W. Hoelle, H. Kreyenberg, D. Niethammer, P. Lang, JF Beck, T. Klingebiel, P. Bader. Outcome of allogeneic stem cell transplantation in children with non malignant diseases. Haematologica 2006: 91(6):788-794.
- P. Bader, A. Willasch, D. Niethammer, T. Klingebiel. Haploidentical stem cell transplantation in Childhood. Current Cancer Therapy Reviews 2007, 3; 37-44.
- A. Willasch, G. Schneider, B. S. Reincke, N. Shayegi, H. Kreyenberg, S. Kuci, G. Weber, Bvd. Reijden, D. Niethammer, T. Klingebiel, P. Bader. Sequence polymorphism systems for quantitative real-time polymerase chain reaction to characterize haematopoietic chimerism - High informativity and sensitivity as well as excellent reproducibility and precision of measurement. Laboratory Hematology 2007 (in press).
|
> |
Co-workers and members of the team:
- OA Jan Sörensen , Dr. med. Andrea Jarisch (clinical trials and patient care)
- Dr. rer. nat. Hermann Kreyenberg (clinical trials , molecular biology)
- Dr. med. Selim Kuçi, Dr. med. Zyrafete Kuçi (cell biology, cell culturing)
- Dr. med. André Willasch (clinical trials , molecular biology)
- Dr. med. Gerrit Weber, Dr. med. Eva Rettinger (T-cell therapies und tumour biology)
|
> |
ZAFES contact person:
|
|
| |
|
|
|
